On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ ... to take profits on rips here being ...
Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...
Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...
Gilead Sciences ( (GILD) ) has released its Q3 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.
Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...
MacroGenics (NASDAQ: MGNX) Q3 2024 Earnings Call Nov 05, 2024, 4:30 p.m. ET ...
In the latest trading session, Gilead Sciences (GILD) closed at $88.08 ... The HIV and hepatitis C drugmaker's stock has climbed by 5.87% in the past month, exceeding the Medical sector's loss ...